BCVA can remain deceptively stable until late RP and becomes insensitive at profound vision loss, motivating ...
Nanoscope Therapeutics, Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to ...
A Johnson & Johnson gene therapy in development for an inherited vision-loss disorder has failed a Phase 3 study, the latest clinical research setback for a rare eye disease that so far has no ...
Many retinal diseases begin long before patients experience noticeable vision loss.Clinicians frequently manage patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results